Hematologic Oncology

Jia Ruan, MD, PhD, associate professor of clinical medicine, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses treatment considerations for patients with relapsed/refractory mantle cell lymphoma.

November 30, 2020 - The FDA has granted a fast track designation to eprenetapopt as a treatment for patients with TP53-mutant acute myeloid leukemia.

The FDA has granted a priority review designation to a new drug application for belumosudil for the treatment of patients with chronic graft-versus-host disease.

Stephen A. Strickland, MD, BS, MS, MSCI, relays insightful questions from the audience to the speakers, who provided insight into how they are navigating the evolving treatment landscape of hematologic malignancies.

Kathleen ​A. Dorritie, MD, discusses transplant eligibility in multiple myeloma.

Olalekan O. Oluwole, MBBS, MD, discusses the approvals of tisagenlecleucel and axicabtagene ciloleucel, along with several research efforts that have been dedicated to the development and exploration of CAR T-cell therapies in the realm of leukemias and lymphomas.

November 23, 2020 - The National Comprehensive Cancer Network has updated its Clinical Practice Guidelines in Oncology for Myelodysplastic Syndromes (MDS) to include the combination of decitabine and cedazuridine as a category 2a recommendation for the treatment of adult patients with intermediate- and high-risk MDS.

Robert M. Dean, MD, discusses remaining challenges in diffuse large B-cell lymphoma.

November 18, 2020 - The FDA has granted a fast track designation to the BTK inhibitor rilzabrutinib for the treatment of patients with immune thrombocytopenia.

November 17, 2020 - The review of the biologics license application for the CAR T-cell product lisocabtagene maraleucel for the treatment of adult patients with relapsed/refractory large B-cell lymphoma following at least 2 previous therapies has been delayed.

November 16, 2020 — The United Kingdom’s National Institute for Health and Care Excellence has recommended caplacizumab-yhdp with plasma exchange and immunosuppression for the treatment of an acute episode of acquired thrombotic thrombocytopenic purpura in adults and those aged 12 years and over who weigh at least 40 kg.

Deepa Jagadeesh, MD, discusses unmet needs in aggressive and rare lymphoma subtypes.

The treatment landscape of relapsed/ refractory multiple myeloma has undergone rapid changes over the past 2 decades, with over a dozen drug approvals by the FDA.